Related Experiment Video
Updated: Apr 4, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Increased Early Postprandial Glucagon Concentrations in Humans With Newly Diagnosed Type 2 Diabetes and Steatotic
Maximilian Huttasch1,2, Sabine Kahl1,2,3, Tim Mori2,4
1Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich Heine University, Düsseldorf, Germany.
Objective:
Glucagon-based polyagonists improve metabolic dysfunction-associated steatotic liver disease (MASLD), which could result from glucagon-stimulated hepatic lipid oxidation. Nevertheless, people with long-standing type 2 diabetes (T2D) exhibit a paradoxical rise in both hepatic lipid content (HLC) and glucagon levels, which has been related to disturbed hepatic metabolism generating glucagonotropic metabolites such as amino acids and nonesterified fatty acids (NEFAs). We examined these relationships in individuals with normal glucose tolerance (NGT) and newly diagnosed T2D.
Research Design And Methods:
Fifty individuals with newly diagnosed T2D and 50 age-, sex-, and BMI-matched individuals with NGT underwent liquid mixed-meal tolerance tests to measure glucagon and metabolites, hyperinsulinemic-euglycemic clamps with stable isotope dilution, indirect calorimetry to assess insulin sensitivity and lipid oxidation, and 1H/31P magnetic resonance spectroscopy and MRI to quantify HLC, ATP, and visceral adipose tissue (VAT) volume.
Results:
Individuals with T2D had an ∼65% higher HLC as well as higher fasting and postprandial glucagonemia (∼30% and ∼75%) than those with NGT. Multivariable linear regression analyses revealed that the presence of MASLD, but not T2D, was associated with higher fasting glucagonemia. Interestingly, postprandial glucagon was related to HLC only in T2D, leading to ∼47% higher early postprandial glucagonemia in individuals with combined MASLD and T2D. These differential associations were independent of insulin sensitivity or VAT volume, and neither were mediated by amino acids or NEFAs.
Conclusions:
Hyperglucagonemia in the face of higher HLC in early T2D is not due to differences in insulin sensitivity or glucagonotropic metabolites but could suggest hepatic glucagon resistance.
Related Concept Videos
Hypoglycemia and Glucagon
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Diabetes Mellitus: Type 2 and Gestational
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Diabetes: Symptoms, Diagnosis, and Complications

